替莫唑胺治疗儿童新诊断的弥漫性脑干胶质瘤：一个破灭的承诺？
Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
作者信息
Rizzo Daniela, Scalzone Maria, Ruggiero Antonio, Maurizi Palma, Attinà Giorgio, Mastrangelo Stefano, Lazzareschi Ilaria, Ridola Vita, Colosimo Cesare, Caldarelli Massimo, Balducci Mario, Riccardi Riccardo
出版信息
J Chemother. 2015 Feb;27(2):106-10. doi: 10.1179/1973947814Y.0000000228. Epub 2014 Dec 2.
BACKGROUND
The purpose of this study was to assess the efficacy and toxicity of radiotherapy (RT) with concurrent temozolomide (TMZ) chemotherapy followed by adjuvant TMZ in children with diffuse intrinsic pontine glioma (DIPG).
METHODS
Patients younger than 18 years with newly diagnosed DIPG were enrolled. Children were treated with focal RT along with concurrent daily TMZ. Four weeks after completing the initial RT-TMZ schedule, adjuvant TMZ was given every 28 days up to 12 cycles or progression disease.
RESULTS
Fifteen children with a median age of 9 years were enrolled. Fourteenth out of the 15 patients completed the chemoradiotherapy. The toxicity associated with TMZ was primarily haematopoietic. At a median follow-up of 15 months 13 children had died and 2 children were alive with progressive disease. No patient experienced complete response (CR). The median time to progression was 7.15 months.
CONCLUSION
Chemoradiotherapy with TMZ followed by adjuvant TMZ did not improve the poor prognosis associated with DIPG in children.
背景
本研究旨在评估放疗（RT）联合替莫唑胺（TMZ）同步化疗后序贯辅助性TMZ治疗弥漫性脑桥胶质瘤（DIPG）患儿的疗效和毒性。
方法
纳入年龄小于18岁的新诊断DIPG患者。患儿接受局部放疗并同步每日服用TMZ。在完成初始RT-TMZ方案4周后，每28天给予辅助性TMZ，最多12个周期或直至疾病进展。
结果
纳入15例中位年龄为9岁的儿童。15例患者中有14例完成了放化疗。与TMZ相关的毒性主要是血液系统毒性。中位随访15个月时，13例儿童死亡，2例儿童存活且疾病进展。无患者达到完全缓解（CR）。中位疾病进展时间为7.15个月。
结论
TMZ同步放化疗后序贯辅助性TMZ并未改善DIPG患儿的不良预后。
Zotero 插件